Clinical Trials Directory

Trials / Completed

CompletedNCT02540109

Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study

Targeted Transcranial Electrotherapy for Stroke Rehabilitation - Exploratory Trial on Aphasia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
58 (actual)
Sponsor
Soterix Medical · Industry
Sex
All
Age
25 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This Phase II study aims to ascertain the effectiveness of HD-tDCS for adjunctive treatment of anomia in chronic aphasia post stroke. Furthermore, it will help explore factors such as alternate outcome measures, subject selection criteria, and benefits of extended treatment duration. These results will be compared to an existing trial using conventional non-targeted tDCS with the same design and outcomes. Patients will be treated with HD-tDCS while performing computerized anomia treatment. The basis behind this method is that language therapy is mediated by cortical areas that are most effectively activated during the training tasks, thus increasing electric stimulation in these areas may improve learning outcomes. To better understand the long term benefits of the adjunctive treatment, patients will be screened again four weeks and six months after study using the same anomia tests. If HD-tDCS shows promising results in increasing the learning outcomes of anomia treatment, a Phase III trial can be considered.

Conditions

Interventions

TypeNameDescription
DEVICEHD-tDCS (Soterix Medical, Active)Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
DEVICEHD-tDCS (Soterix Medical, Sham)Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.

Timeline

Start date
2015-07-01
Primary completion
2019-09-01
Completion
2019-09-01
First posted
2015-09-03
Last updated
2023-12-05

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02540109. Inclusion in this directory is not an endorsement.